- Home
- KEQU vs DMAC Comparison
KEQU vs DMAC Comparison
Compare KEQU & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEQU
- DMAC
- Stock Information
- Founded
- KEQU 1906
- DMAC 2000
- Country
- KEQU United States
- DMAC United States
- Employees
- KEQU N/A
- DMAC N/A
- Industry
- KEQU Medical Specialities
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- KEQU Industrials
- DMAC Health Care
- Exchange
- KEQU Nasdaq
- DMAC Nasdaq
- Market Cap
- KEQU 154.8M
- DMAC 172.7M
- IPO Year
- KEQU N/A
- DMAC N/A
- Fundamental
- Price
- KEQU $43.70
- DMAC $4.70
- Analyst Decision
- KEQU
- DMAC Strong Buy
- Analyst Count
- KEQU 0
- DMAC 3
- Target Price
- KEQU N/A
- DMAC $7.00
- AVG Volume (30 Days)
- KEQU 13.9K
- DMAC 105.5K
- Earning Date
- KEQU 12-04-2024
- DMAC 11-13-2024
- Dividend Yield
- KEQU N/A
- DMAC N/A
- EPS Growth
- KEQU 359.78
- DMAC N/A
- EPS
- KEQU 6.24
- DMAC N/A
- Revenue
- KEQU $202,309,000.00
- DMAC N/A
- Revenue This Year
- KEQU N/A
- DMAC N/A
- Revenue Next Year
- KEQU N/A
- DMAC N/A
- P/E Ratio
- KEQU $7.00
- DMAC N/A
- Revenue Growth
- KEQU N/A
- DMAC N/A
- 52 Week Low
- KEQU $16.51
- DMAC $2.14
- 52 Week High
- KEQU $55.62
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- KEQU 73.35
- DMAC 63.73
- Support Level
- KEQU $41.88
- DMAC $3.96
- Resistance Level
- KEQU $44.54
- DMAC $4.21
- Average True Range (ATR)
- KEQU 1.84
- DMAC 0.21
- MACD
- KEQU 0.84
- DMAC 0.02
- Stochastic Oscillator
- KEQU 91.16
- DMAC 87.64
About KEQU Kewaunee Scientific Corporation
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The company operates through two segments: Domestic and International. The Domestic business segment designs manufacture and install scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, work surfaces, workstations, workbenches, and computer enclosures. The International business segment provides facility design, engineering, construction and project management from the planning stage through the testing and commissioning of laboratories. The company generates a majority of its revenue from the Domestic business segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.